# Non-Hodgkin Lymphoma

Non-Hodgkin lymphoma requires rapid conversion of a suspected lymphoid malignancy into a specific histologic diagnosis, stage, and tempo category. Management diverges sharply between aggressive entities requiring prompt systemic therapy and indolent entities in which symptom burden and disease distribution determine treatment timing.

**Clinical question:** How should physicians establish, stage, risk-stratify, and direct initial management for suspected non-Hodgkin lymphoma?

Updated: 2026-08-21T02:18:10.094748+00:00

## What matters in practice
- Do not treat a presumed NHL subtype from imaging or peripheral blood findings alone; obtain tissue adequate for morphology and immunophenotyping because histology determines urgency, staging strategy, and treatment. [1][10]
- Rapid clinical progression, B symptoms, bulky or threatening extranodal disease, and a Burkitt-like presentation should accelerate hematology-oncology management because aggressive lymphomas may be fatal within weeks without treatment. [11][14]
- Use PET/CT for staging and response assessment in FDG-avid lymphoma; residual metabolic activity in NHL has limited positive predictive value and may require repeat imaging or biopsy before changing treatment. [16][17]
- For indolent NHL, treatment timing depends on symptoms and disease burden; for aggressive NHL, subtype-specific systemic therapy is generally required promptly. [1][11]
- Relapsed/refractory aggressive B-cell lymphomas may be candidates for anti-CD19 CAR T-cell therapy after multiple prior therapies; treatment selection requires attention to disease tempo, bridging needs, and cellular-therapy toxicities. [19][23]

## Identify presentations that require expedited lymphoma management

Determine disease tempo and immediately threatened organ systems before completing full staging.

Escalate urgently when the clinical course suggests aggressive NHL: rapidly enlarging adenopathy or extranodal masses, constitutional symptoms, suspected CNS disease, gastrointestinal obstruction, or a Burkitt-like rapidly progressive presentation. Aggressive entities include diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, lymphoblastic lymphoma/leukemia, adult T-cell leukemia/lymphoma, and other peripheral T-cell lymphomas; untreated aggressive disease can cause death within weeks. [11][14]

A slowly waxing and waning nodal course favors an indolent process such as follicular lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, or splenic marginal zone lymphoma, but does not eliminate transformation or clinically consequential extranodal disease. The management question is not merely whether lymphoma is present: determine whether symptoms, site-specific compromise, or biologic tempo requires immediate treatment. [1][11]

Localizing symptoms direct the immediate branch of evaluation. Headache or focal neurologic findings raise concern for primary CNS lymphoma; nausea, early satiety, vomiting, abdominal fullness, weight loss, or obstruction symptoms suggest gastrointestinal involvement. These presentations require site-directed imaging and coordinated diagnostic planning rather than routine outpatient surveillance. [11]
- Prioritize immediate hematology-oncology involvement for suspected Burkitt lymphoma, DLBCL with rapid progression, peripheral T-cell lymphoma, lymphoblastic lymphoma, or organ-threatening extranodal disease. [11][14]
- Ask specifically about prior or current immunosuppression, autoimmune disease, hepatitis C virus exposure, and human T-cell lymphotropic virus type 1 exposure because these factors can alter the etiologic differential and subtype-directed testing. [1][13]
- Include HTLV testing when clinically indicated during the NHL evaluation. [1]

*Clinical tempo and site of disease determine the urgency of diagnostic and treatment planning. [1][11][14]*

| Presentation pattern | More likely clinical branch | Next decision |
| --- | --- | --- |
| Rapid progression, B symptoms, marked systemic illness | Aggressive lymphoma, including DLBCL, Burkitt lymphoma, lymphoblastic lymphoma, or peripheral T-cell lymphoma [11][14] | Expedite tissue diagnosis, staging, and subtype-specific treatment planning because untreated aggressive disease may progress over weeks. [11] |
| Waxing and waning adenopathy over years | Indolent lymphoma, including follicular lymphoma, CLL/SLL, or splenic marginal zone lymphoma [11] | Establish subtype and assess symptoms, distribution, and disease burden before deciding whether treatment is required. [1][11] |
| Headache or other CNS-localizing symptoms | Primary CNS lymphoma or secondary CNS involvement [11] | Obtain urgent CNS-directed diagnostic assessment and involve lymphoma specialists. [1][11] |
| Early satiety, vomiting, abdominal fullness, or obstruction symptoms | Primary gastrointestinal lymphoma or extranodal involvement [11] | Assess for visceral obstruction and obtain site-directed diagnostic evaluation. [11] |

## Obtain pathology that can distinguish the therapeutic entity

NHL is a classification problem before it is a treatment problem.

Obtain tissue from the most accessible clinically representative involved site and ensure that morphology and immunophenotyping can be performed. NHL arises from B cells, T cells, or NK cells and encompasses clinically distinct entities; treatment varies by histologic subtype, site of involvement, stage, and symptom severity. [1][11]

Request hematopathology review with flow-cytometric immunophenotyping when appropriate. Immunophenotyping improved diagnostic accuracy by approximately 10% to 45% in mantle cell lymphoma, DLBCL, and T-cell lymphomas in a clinical evaluation of lymphoma classification, underscoring why morphologic diagnosis alone may be insufficient for treatment selection. [10]

Use the pathology result to assign the patient to a therapeutic branch rather than relying on the umbrella diagnosis of NHL. DLBCL is the most common NHL subtype and is aggressive; follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, primary CNS lymphoma, and peripheral T-cell/NK-cell lymphomas have materially different expected tempo, staging needs, and treatment approaches. [1][11][13]
- Communicate suspected transformation, rapid clinical tempo, immunosuppression, and extranodal location to pathology because clinical context assists classification of heterogeneous large B-cell and T-cell processes. [1][13]
- Do not infer an indolent course solely from nodal distribution; DLBCL may arise in nodal or extranodal sites, including gastrointestinal tract, testis, and CNS. [13]
- Recognize that marginal zone lymphoma comprises extranodal MALT-type, nodal, and splenic forms, which should not be managed as a single interchangeable entity. [12]

*Selected NHL branches requiring different management pathways. [1][11][12][13]*

| Entity or group | Clinical implication | Management consequence |
| --- | --- | --- |
| DLBCL | Aggressive B-cell lymphoma; the most common adult NHL subtype and may be nodal or extranodal. [13] | Complete staging and initiate prompt curative-intent systemic treatment planning after diagnostic classification. [1][11] |
| Burkitt lymphoma | Rapid onset and aggressive clinical behavior. [14] | Treat as an urgent hematologic malignancy after expedited diagnostic confirmation and assessment for CNS involvement. [14][24] |
| Follicular lymphoma | Typically indolent with potentially prolonged waxing and waning adenopathy. [11] | Base treatment timing on symptoms and disease burden rather than lymphoma presence alone. [1] |
| Mantle cell lymphoma | A distinct B-cell lymphoma in which immunophenotyping materially improves diagnostic accuracy. [10] | Use subtype-specific treatment and relapse planning; CAR T-cell therapy is an established option in relapsed/refractory disease. [20][21] |
| Peripheral T-cell and NK/T-cell lymphomas | Generally included among aggressive T-cell lymphoma branches. [1][11] | Avoid extrapolating indolent B-cell lymphoma management; pursue subtype-specific systemic treatment planning. [1] |

## Stage with PET/CT when lymphoma is FDG-avid and interpret residual uptake cautiously

Imaging should establish baseline extent and provide an interpretable comparator for response.

Use PET/CT for initial staging of FDG-avid lymphomas and for interim or end-of-treatment response assessment within the Lugano framework. PET/CT has prognostic value across multiple FDG-avid NHL categories, including Burkitt, mantle cell, follicular, NK-cell, and T-cell lymphomas. [16][17]

Use the Deauville 5-point score with PET/CT-based response assessment in FDG-avid disease. In NHL, PET/CT has high negative predictive value, reported at 80% to 100%, but its positive predictive value is lower and variable, reported at 50% to 100%; metabolically active residual lesions therefore warrant confirmation with further imaging or biopsy when the result would trigger a major treatment change. [16]

For non-FDG-avid lymphomas assessed by CT, use Lugano quantitative measurements. Target lymph nodes require a long-axis measurement greater than 1.5 cm, extranodal lesions must measure at least 1.0 cm, and up to six nodal and/or extranodal target lesions are incorporated into bidimensional response measurements. [16]
- Document baseline nodal, extranodal, splenic, and CNS-relevant disease sites before treatment because subsequent response classification depends on baseline disease mapping. [16][17]
- Do not equate a positive end-of-treatment PET/CT with viable lymphoma without considering biopsy or interval reassessment, particularly when salvage treatment would be consequential. [16]
- In Burkitt lymphoma, assess for CNS involvement because involvement is reported at diagnosis in approximately 20% to 30% of patients and is predominantly leptomeningeal. [24]

*Response assessment differs according to FDG avidity. [16][17]*

| Disease assessment setting | Preferred framework | Interpretation that changes management |
| --- | --- | --- |
| FDG-avid NHL at staging, interim assessment, or end of treatment | PET/CT with Lugano response assessment and Deauville 5-point scoring [16][17] | A negative PET/CT is prognostically informative; persistent uptake has lower positive predictive value and may require biopsy or further imaging before treatment escalation. [16] |
| Non-FDG-avid lymphoma | CT-based Lugano quantitative assessment [16] | Measure qualifying nodes greater than 1.5 cm in long axis and qualifying extranodal lesions at least 1.0 cm; assess up to six target lesions. [16] |

## Match treatment timing and intensity to lymphoma biology

Histology, stage, involved site, symptoms, and patient fitness determine first-line strategy.

For aggressive NHL, move from classification to subtype-specific systemic treatment planning without delay. DLBCL is the principal aggressive B-cell branch; R-CHOP has remained the longstanding frontline regimen and successfully treats more than 50% of patients with DLBCL, although refractory disease and relapse remain common. [23]

For indolent B-cell lymphomas, treatment initiation is driven by symptom severity and clinical impact, not simply by radiographic disease detection. Follicular lymphoma, CLL/SLL, and splenic marginal zone lymphoma may follow a prolonged course, while disease location can create indications for intervention even when systemic symptoms are absent. [1][11]

Do not use a single treatment framework across B-cell, T-cell, NK-cell, CNS, and gastrointestinal lymphoma. Primary CNS lymphoma, extranodal gastrointestinal lymphoma, marginal zone subtypes, mantle cell lymphoma, and peripheral T-cell lymphomas require disease-specific planning based on site, pathology, and stage. [1][12]
- Before anthracycline-containing therapy is selected for DLBCL, integrate age, performance status, and comorbidities into regimen fitness assessment; treatment selection varies with these patient factors. [11][23]
- For aggressive B-cell lymphoma with relapse or refractory disease, reassess chemosensitivity, transplant candidacy, and eligibility for CAR T-cell therapy rather than presuming that repeated conventional chemotherapy is optimal. [19][23]
- For patients with apparent isolated extranodal disease, confirm whether the site represents a distinct lymphoma entity, because primary CNS, MALT-type marginal zone, and primary mediastinal large B-cell lymphoma are classified and managed differently from generic nodal NHL. [1][10][12]

### Relapsed or refractory aggressive B-cell lymphoma

Anti-CD19 CAR T-cell therapy is potentially curative in multiple-relapsed or refractory aggressive B-cell lymphomas. Pivotal studies of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel enrolled patients after at least two prior lines of therapy, including patients with chemoresistant disease or relapse within one year after autologous stem-cell transplantation. [19][23]

Refer early to a cellular-therapy center when CAR T-cell therapy is under consideration because disease control while manufacturing proceeds may require bridging therapy. In pivotal large B-cell lymphoma studies, bridging therapy policies differed: ZUMA-1 permitted glucocorticoids only, whereas approximately 90% of JULIET participants and 60% of TRANSCEND-NHL-001 participants received bridging therapy. [23]

Monitor for treatment-specific toxicities, including cytokine release syndrome and tumor lysis syndrome; TLS can occur after CAR T-cell therapy. [8][18]
- Mantle cell lymphoma is another relapsed/refractory B-cell NHL setting with approved CAR T-cell therapy; reported liso-cel study eligibility included at least two prior systemic regimens with prior alkylator, BTK inhibitor, and anti-CD20 exposure. [20][21]
- For transplant-eligible large B-cell lymphoma, autologous stem-cell transplantation remains a relevant comparator and option in selected relapse settings; treatment sequencing should be individualized to timing of relapse and chemosensitivity. [23]

*Treatment branchpoints after diagnostic classification. [1][11][19][20][23]*

| Clinical branch | Treatment timing principle | Escalation pathway |
| --- | --- | --- |
| Aggressive DLBCL or other high-grade NHL | Prompt systemic treatment planning after definitive classification because untreated aggressive NHL can be rapidly fatal. [11] | At relapse or refractory disease, assess transplant strategy and early CAR T-cell referral. [19][23] |
| Indolent lymphoma without clinically consequential symptoms | Symptoms and disease burden inform when to start treatment. [1] | Continue structured reassessment for symptom progression, organ compromise, or evidence of transformation. [1][11] |
| Relapsed/refractory aggressive B-cell lymphoma after multiple therapies | Consider anti-CD19 CAR T-cell therapy, which may be potentially curative. [19][23] | Plan bridging therapy when needed and monitor for CRS and TLS. [8][18][23] |
| Relapsed/refractory mantle cell lymphoma | Use subtype-specific relapse sequencing. [1][20] | CAR T-cell therapy is an approved treatment option; assess prior alkylator, BTK inhibitor, and anti-CD20 exposure. [20][21] |

## Use clinical change and response imaging to trigger reassessment

Monitoring should detect progression, transformation, residual active disease, and treatment toxicity early enough to alter management.

During observation of indolent disease, reassess at each visit for new constitutional symptoms, accelerating adenopathy, extranodal symptoms, splenic or abdominal symptoms, and declining functional status. A change from a prolonged waxing-and-waning course to a rapidly progressive systemic illness should prompt repeat tissue evaluation for a more aggressive lymphoma component rather than automatic continuation of an indolent-lymphoma plan. [1][11]

After treatment of FDG-avid NHL, compare interim and end-of-treatment PET/CT results with baseline imaging using Lugano/Deauville interpretation. A metabolically inactive result carries favorable prognostic information, while isolated or equivocal residual uptake should be investigated with repeat imaging or biopsy when confirmation would determine salvage therapy, radiation, transplantation, or cellular therapy. [16]

In patients receiving CAR T-cell therapy, monitor actively for cytokine release syndrome and tumor lysis syndrome. Because cellular-therapy trials enrolled patients with high-risk chemorefractory disease and commonly used bridging treatment, transition planning should include toxicity surveillance and reassessment of lymphoma control after infusion. [8][18][23]
- Re-biopsy a new or discordantly progressive FDG-avid lesion when feasible before assigning refractory disease, particularly because PET positivity in NHL is not uniformly specific for viable tumor. [16]
- Use CT-based measurable-disease criteria when PET is not the appropriate assessment modality for a non-FDG-avid lymphoma. [16]
- Reassess CNS-directed symptoms promptly in high-risk histologies, especially Burkitt lymphoma, in which CNS involvement is common at diagnosis. [24]

*Events that should change the monitoring plan. [1][8][11][16][18][24]*

| Monitoring finding | Interpretation | Next action |
| --- | --- | --- |
| New B symptoms or rapidly enlarging disease during an indolent course | Possible aggressive biology or transformation [11] | Expedite repeat diagnostic evaluation and hematology-oncology reassessment. [1][11] |
| Residual PET avidity after therapy | Possible active disease, but positive predictive value is variable in NHL [16] | Use biopsy or additional imaging when the result will alter definitive salvage management. [16] |
| Neurologic symptoms in Burkitt lymphoma | Possible CNS involvement, which occurs at diagnosis in approximately 20% to 30% of cases [24] | Perform urgent CNS-directed assessment and integrate findings into treatment planning. [24] |
| Fever or inflammatory toxicity after CAR T-cell therapy | Possible cytokine release syndrome [18] | Initiate cellular-therapy toxicity evaluation and management pathway. [18] |

## References
1. Non-Hodgkin lymphoma - Symptoms, diagnosis and treatment | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/zh-cn/312
2. Normative data for flow cytometry immunophenotyping ... — jcp.bmj.com — https://jcp.bmj.com/content/71/2/174
3. Normative data for flow cytometry immunophenotyping of ... — jcp.bmj.com — https://jcp.bmj.com/content/jclinpath/71/2/174.full.pdf
4. The Lancet Specialty Collections: Lymphoma — www.thelancet.com — https://www.thelancet.com/collections/lymphoma?parent=001788&rel=nofollow&Ppub=%5B20230303+TO+20250303%5D&startPage=0&pageSize=100
5. A Prognostic Index for Systemic AIDS-Related Non ... — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/0003-4819-143-4-200508160-00007
6. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0923753419372114
7. B Cell Lymphoma - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/b-cell-lymphoma
8. Renal outcomes after chimeric antigen receptor... — journals.lww.com — https://journals.lww.com/00005884-202209000-00023
9. Next-Gen immunotherapy inhematological... : Oncology and Translational Medicine — journals.lww.com — https://journals.lww.com/01873671-990000000-00147
10. A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma | Blood | American Society of Hematology — ashpublications.org — https://ashpublications.org/blood/article/89/11/3909/138866/A-Clinical-Evaluation-of-the-International
11. Non-Hodgkin Lymphoma - PubMed — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32644754
12. Chapter 23: Non-Hodgkin lymphomas - ASH Publications — ashpublications.org — https://ashpublications.org/books/book/6/chapter/77771/Non-Hodgkin-lymphomas
13. Non-Hodgkin lymphoma - World Cancer Report - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/n/iarcwcr2020/sec5.19
14. Chapter 45: Aggressive non-Hodgkin and Burkitt lymphomas — ashpublications.org — https://ashpublications.org/books/book/10/chapter/12747144/Aggressive-non-Hodgkin-and-Burkitt-lymphomas
15. 23: Aggressive non-Hodgkin and Burkitt lymphoma — ashpublications.org — https://ashpublications.org/books/book/8/chapter/10651017/Aggressive-non-Hodgkin-and-Burkitt-lymphoma
16. PET/CT Tumor Response Assessment Criteria into Daily Practice — www.ajnr.org — https://www.ajnr.org/content/early/2019/11/28/ajnr.A6294.full.pdf
17. Recommendations for Initial Evaluation, Staging, and Response ... — ascopubs.org — https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2013.54.8800?role=
18. Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibody Use in Earlier Lines of Treatment of Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma — ascopubs.org — https://ascopubs.org/doi/10.1200/EDBK-25-473302
19. A New Era of Targeted Therapy in Non-Hodgkin Lymphoma — ascopubs.org — https://ascopubs.org/doi/10.1200/EDBK_279043
20. Breyanzi; INN-lisocabtagene maraleucel — www.ema.europa.eu — https://www.ema.europa.eu/en/documents/variation-report/breyanzi-vr-0000265024-epar-assessment-report-variation_en.pdf
21. Three-Year Follow-Up of KTE-X19 in Patients With ... — ascopubs.org — https://ascopubs.org/doi/10.1200/JCO.21.02370
22. Kite Pharma, Inc. - HMA-EMA Catalogues — catalogues.ema.europa.eu — https://catalogues.ema.europa.eu/system/files/2026-04/KT-EU-471-0117-appendix-16.1.1.%20protocol%20amendment%2008_f-redact.pdf
23. CAR T-Cell Therapy or Autologous Stem Cell Transplant in Large B-Cell Lymphoma: Achieving Goals, Best Possible Outcomes — dailynews.ascopubs.org — https://dailynews.ascopubs.org/do/car-t-cell-therapy-autologous-stem-cell-transplant-large-b-cell-lymphoma-achieving
24. Central Nervous System Prophylaxis and Treatment in ... — dailynews.ascopubs.org — https://dailynews.ascopubs.org/do/central-nervous-system-prophylaxis-and-treatment-burkitt-lymphoma

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.